Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients

R.P Rocconi,J.K Chan,M Barve,D Tewari,J.N Bottsford-Miller,M Tang,P Aaron,G Wallraven,E Bognar,L Manning,J Nemunaitis,D Shanahan,B Slomovitz,T.J Herzog,B.J Monk,R.L Coleman

doi:10.1016/j.ygyno.2020.06.108

Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients

R.P Rocconi, J.K Chan + Show 14 more

https://doi.org/10.1016/j.ygyno.2020.06.108

Copy DOI

Journal: Gynecologic oncology	Publication Date: Oct 1, 2020
Citations: 3

Affiliation: University of South Alabama, Mary Crowley Cancer Research Center, Biostatistical Consulting (United States), Gradalis (United States), Sylvester Comprehensive Cancer Center, University of Cincinnati, The University of Texas MD Anderson Cancer Center

#Poor Prognosis In Ovarian Cancer #Improvement In Relapse-free Survival + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objective: Despite advances, overall prognosis for advanced epithelial ovarian cancer (EOC) remains poor. Considering elevated TGFβ expression correlates with poor prognosis in ovarian cancer, this study aims to determine whether a maintenance vigil could provide improvement in relapse-free survival. Vigil is an autologous tumor cell vaccine constructed from autologous harvested tumor tissue transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin, thereby creating TGFβ expression control.

Full Text